Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.
Miguel Gonzalez VelezHeidi E KosiorekJan B EganAndrea L McNattyIrbaz B RiazSteven R HwangGlenn A StewartThai H HoCassandra N MooreParminder SinghRenee K SharpstenBrian A CostelloAlan H BrycePublished in: Prostate cancer and prostatic diseases (2021)
The presence of TSG-alt outperforms clinical criteria for predicting early progression during first-line treatment of M1-HSPC. ADT + A was less effective in patients with than without TSG-alt. Confirmation of these findings may establish the need for inclusion of molecular stratification in treatment algorithms.